CEL-SCI Corporation
8229 Boone Boulevard, Suite 802
Vienna, VA 22182, USA
Phone: (703) 506-9460
gdewindt@cel-sci.com
www.cel-sci.com

Company Overview

CEL-SCI completed the world's largest Phase 3 study in head and neck cancer and reported data showing a significant survival benefit with no safety issues in patients who received its Multikine®* immunotherapy prior to a standard of care treatment of surgery plus radiotherapy. The Company is preparing to file for FDA approval for this population comprising about 210,000 patients per year worldwide. CEL-SCI's goal is to activate the immune system to fight cancer BEFORE surgery, radiation, and chemotherapy have damaged it. Typically, cancer immunotherapy drugs are given after those first treatments. Head and neck cancer is a multi-billion dollar global market and Multikine has received Orphan Drug designation from the FDA for this indication, an unmet medical need for which the FDA has not approved a new treatment in 60 years. CEL-SCI is also developing a novel vaccine for the treatment of rheumatoid arthritis using the LEAPS technology platform which has been supported by multiple grants from the NIH.

EQUITY OVERVIEW*

NYSE American: CVM

Stock Price: ~$8.00

Trading Volume (90 day average): 2 M

Shares Outstanding: ~ 43 M

Market Cap: about $350 M

Cash on Hand: $47 M

*As of July 1, 2021

UPCOMING MILESTONES

- **Pre-Biologics License Application (BLA) meeting with FDA**
- **Finalize and submit clinical report to FDA**
- **Submit data for peer review in top scientific journals**

IP & MANUFACTURING

- **Robust patent portfolio for Multikine in U.S., Europe, China, and Japan**
- **In-house 73,000 sq. ft. cGMP manufacturing facility produced Multikine for clinical trials**
- **Recent expansion and upgrades to manufacturing facility preparing for commercialization**
- **$100 M spent on the manufacturing facility, development, and validation of Multikine**

HEAD & NECK CANCER MARKET

- **890,000 new cases each year**
- **CEL-SCI's target population is 210,000 per year**
- **Global Phase 3 study spanned 20 countries; FDA approval expected to lead to approval in many countries**

Investment Highlights

Multikine Modulates & Mobilizes Intact Immune Response to Kill Cancer

Multikine is a copy of the pro-inflammatory cytokine immune response our bodies produce every day and is designed to allow a person's intact immune system cells to attack their own cancer. Patients are treated with Multikine right after diagnosis, before any other standard of care treatment. The goal is to help the intact immune response detect and kill the tumor and micro-metastases to reduce recurrence and improve overall survival. In CEL-SCI's Phase 3 study, Multikine immunotherapy produced a very significant 14.1% 5-year survival benefit (62.7% vs 48.6%) in the treatment arm (n=380) receiving Multikine prior to surgery plus radiotherapy, as compared to the control group which received only surgery plus radiotherapy.

Multikine Treatment Regimen Schematic



Proposed New 1st Line SOC* for patients receiving Surgery and Radiotherapy only

Phase 3 Trial Reports Positive Results: Preparing to File for FDA Approval

928 patients were randomized into two treatment arms determined by risk of recurrence post-surgery following National Cancer Comprehensive Network (NCCN) guidelines. 41.2% of patients were prescribed surgery + radiation (no chemotherapy) based on NCCN guidelines; and 50.6% were prescribed surgery + chemoradiotherapy (chemotherapy and radiation concurrently) based on NCCN guidelines. 8.2% were excluded from the analysis who did not receive radiation or chemotherapy due to doctor, family, and patient decisions. In the treatment arm that was prescribed surgery + radiation (no chemotherapy), Multikine immunotherapy produced a statistically significant 14.1% 5-year survival benefit. 62.7% of patients treated with Multikine were alive 5-years after treatment as compared to 48.6% for patients who did not receive Multikine. The survival benefit imparted by Multikine as compared to survival in the control group increased over time. Patients who received chemotherapy (cisplatin) as part of their prescribed standard of care treatment did not benefit from Multikine, indicating that cisplatin may have negated Multikine's survival benefits. No safety issues were found in the whole study population.

LEAPS Therapeutic Vaccines for Rheumatoid Arthritis and COVID-19

LEAPS is CEL-SCI's second proprietary technology platform. It is a new class of drug that acts early to treat autoimmune and infectious diseases. Research has been funded via collaborations with the U.S. National Institutes of Health (NIH), U.S. Army, Navy, and universities. The first indication is for the treatment of rheumatoid arthritis. The program has also been supported by multiple grants from the NIH.